Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
4sc AG
Headquarters: Planegg-Martinsried, Germany
Website: http://www.4sc.com
Year Founded: 1997
Status: Public
Industry Sector: HealthTechnology
CEO: Jason Loveridge, PhD
Number Of Employees: 17
Enterprise Value: $-1,147,030
PE Ratio: -10.49
Exchange/Ticker 1: Xetra:VSC
Exchange/Ticker 2: N/A
Latest Market Cap: $32,409,370
BioCentury | Nov 25, 2020
Product Development
Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline
At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and
BioCentury | Oct 30, 2020
Distillery Therapeutics
KSP as a neuroblastoma target
DISEASE CATEGORY: Cancer
INDICATION: Neuroendocrine tumors Inhibiting the mitotic kinesin KSP could treat neuroblastoma, a pediatric sympathetic nervous system malignancy. In neuroblastoma patients,
INDICATION: Neuroendocrine tumors Inhibiting the mitotic kinesin KSP could treat neuroblastoma, a pediatric sympathetic nervous system malignancy. In neuroblastoma patients,
BioCentury | Feb 1, 2020
Product Development
BioNTech’s approach to matching technologies to tumors
How BioNTech is choosing which technologies to apply to different cancer settings
BioCentury | Dec 15, 2017
Clinical News
4SC reports Phase I data for resminostat in pancreatic and biliary tract cancer
BioCentury | Apr 14, 2017
Emerging Company Profile
Tolerating DHODH
How Immunic plans to differentiate its oral DHODH inhibitor in IBD
Items per page:
1 - 10 of 162